December 8, 2025BloodOpen Access

Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Population-based analysis reveals improved survival with novel therapies in chronic lymphocytic leukemia and highlights mortality trends.

Improved overall survival among chronic lymphocytic leukemia patients during the novel agent era, indicating effective treatment options available now.
Patients receiving novel agent therapy like ibrutinib have shown a 5-year overall survival rate of 65.3%, compared to 61.0% with traditional chemoimmunotherapy.
Analysis of SEER database data from 9913 individuals diagnosed showed significant changes in cause of death patterns from CLL/SLL over different eras.
Findings suggest a need for further exploration into mortality due to cardiovascular diseases and the impacts of new treatment methods.

Voutsinas et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark